Rezolute, Inc. (NASDAQ:RZLT) Short Interest Up 19.3% in February

Rezolute, Inc. (NASDAQ:RZLT) saw a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 2,160,000 shares, a growth of 19.3% from the February 13th total of 1,810,000 shares. Currently, 4.4% of the company’s shares are short sold. Based on an average daily trading volume, of 452,800 shares, the days-to-cover ratio is currently 4.8 days.

Insider Activity at Rezolute

In other news, Director Wladimir Hogenhuis acquired 10,000 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now owns 77,267 shares in the company, valued at $363,154.90. The trade was a 14.87 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 18.39% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Rezolute

Several hedge funds have recently added to or reduced their stakes in RZLT. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute in the third quarter worth about $65,000. Jacobs Levy Equity Management Inc. bought a new position in shares of Rezolute during the third quarter valued at approximately $239,000. State Street Corp raised its holdings in shares of Rezolute by 11.6% in the third quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after buying an additional 13,000 shares during the period. XTX Topco Ltd lifted its stake in shares of Rezolute by 67.4% during the 3rd quarter. XTX Topco Ltd now owns 56,375 shares of the company’s stock worth $273,000 after acquiring an additional 22,704 shares during the last quarter. Finally, MML Investors Services LLC purchased a new position in Rezolute during the 3rd quarter valued at $57,000. 82.97% of the stock is currently owned by institutional investors.

Rezolute Stock Down 0.6 %

RZLT stock traded down $0.02 during midday trading on Wednesday, hitting $3.35. The company’s stock had a trading volume of 180,954 shares, compared to its average volume of 463,274. The company has a 50 day moving average of $4.56 and a two-hundred day moving average of $4.85. Rezolute has a 12 month low of $1.74 and a 12 month high of $6.19. The firm has a market capitalization of $202.79 million, a price-to-earnings ratio of -2.75 and a beta of 0.95.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.11. On average, analysts anticipate that Rezolute will post -0.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on RZLT shares. Guggenheim restated a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Thursday, February 13th. JMP Securities boosted their price objective on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, February 13th. Finally, Craig Hallum upgraded shares of Rezolute to a “strong-buy” rating in a report on Tuesday, February 4th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $24.38.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.